Spots Global Cancer Trial Database for t cell lymphoma
Every month we try and update this database with for t cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | NCT05230680 | T Cell Lymphoma | ACHOP | 20 Years - 85 Years | Samsung Medical Center | |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | NCT00880867 | B Cell Lymphoma T Cell Lymphoma | Poly-ICLC | 18 Years - | Nevada Cancer Institute | |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | NCT05230680 | T Cell Lymphoma | ACHOP | 20 Years - 85 Years | Samsung Medical Center | |
| LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor | NCT04973527 | T Cell Lymphoma T-cell Leukemia | Efficacy of LCA... | 18 Years - 75 Years | Beijing Boren Hospital | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | NCT04653649 | Hodgkin Lymphom... T Cell Lymphoma | HSP-CAR30 | 18 Years - 70 Years | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | NCT05367856 | T Cell Lymphoma | Chidamide combi... | 18 Years - 65 Years | Ruijin Hospital | |
| Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma | NCT04840875 | T Cell Lymphoma T-cell Leukemia | chimeric antige... | - 70 Years | Beijing Boren Hospital | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | NCT05772728 | T Cell Lymphoma | Cidapenem combi... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | NCT00880867 | B Cell Lymphoma T Cell Lymphoma | Poly-ICLC | 18 Years - | Nevada Cancer Institute | |
| Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma | NCT04840875 | T Cell Lymphoma T-cell Leukemia | chimeric antige... | - 70 Years | Beijing Boren Hospital | |
| CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies | NCT04162340 | T Cell Lymphoma... Refractory T-Ce... | CD4 CAR T cells | 18 Years - | iCell Gene Therapeutics | |
| Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma | NCT00974324 | T Cell Lymphoma | endostar and CH... | 18 Years - 75 Years | Fudan University | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | NCT01746173 | T-cell Non-Hodg... | Cyclophosphamid... Doxorubicin Vincristine Etoposide Prednisone Filgrastim Plerixafor Stem Cell Colle... Palifermin Gemcitabine Busulfan Melphalan Stem Cell Trans... | 18 Years - 70 Years | Dana-Farber Cancer Institute | |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma | NCT03703375 | Lymphoma, T-Cel... | Azacitidine Romidepsin Gemcitabine | 18 Years - | Celgene | |
| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) | NCT05230680 | T Cell Lymphoma | ACHOP | 20 Years - 85 Years | Samsung Medical Center | |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | NCT04653649 | Hodgkin Lymphom... T Cell Lymphoma | HSP-CAR30 | 18 Years - 70 Years | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas | NCT01198665 | Peripheral T Ce... Anaplastic Larg... Angioimmunoblas... Cutaneous T Cel... | RAD001 (Everoli... | 20 Years - 70 Years | Samsung Medical Center | |
| Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | NCT05772728 | T Cell Lymphoma | Cidapenem combi... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies | NCT04162340 | T Cell Lymphoma... Refractory T-Ce... | CD4 CAR T cells | 18 Years - | iCell Gene Therapeutics | |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma | NCT03703375 | Lymphoma, T-Cel... | Azacitidine Romidepsin Gemcitabine | 18 Years - | Celgene | |
| A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | NCT05852028 | Lymphoma DLBCL T Cell Lymphoma | Selinexor | - | Ruijin Hospital | |
| Trial of Endostar Combined With CHOPT for T Cell Lymphoma | NCT01430013 | T Cell Lymphoma | Endostar and CH... | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma | NCT00877656 | T Cell Lymphoma | HuMax-CD4 | 18 Years - | Emergent BioSolutions | |
| Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma | NCT04840875 | T Cell Lymphoma T-cell Leukemia | chimeric antige... | - 70 Years | Beijing Boren Hospital | |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | NCT04502446 | T Cell Lymphoma | CTX130 | 18 Years - | CRISPR Therapeutics | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma | NCT03770000 | T Cell Lymphoma | Tenalisib Romidepsin | 18 Years - | Rhizen Pharmaceuticals SA | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas | NCT04334174 | T Cell Lymphoma | Brentuximab Ved... | 18 Years - | University of Kansas Medical Center | |
| LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor | NCT04973527 | T Cell Lymphoma T-cell Leukemia | Efficacy of LCA... | 18 Years - 75 Years | Beijing Boren Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
